The thymidine analog 3'-azido-3'-deoxythymidine (BW A509U, azidothymidine) can inhibit human immunodeficiency virus (HIV) replication effectively in the 50-500 nM range [Mitsuya, H., Weinhold, K. J., Furman, P. A., St. Clair, M. H., Nusinoff-Lehrman, S., Gallo, R. C., Bolognesi, D., Barry, D. W. & Broder, S. (1985) Proc. Naul. Acad. Sci. USA 82,[7096][7097][7098][7099][7100]. In contrast, inhibition of the growth of uninfected human fibroblasts and lymphocytes has been observed only at concentrations above 1 mM. The nature of this selectivity was investigated. Azidothymidine anabolism to the 5'-mono-, -di-, and -triphosphate derivatives was similar in uninfected and HIV-infected cells. The level of azidothymidine monophosphate was high, whereas the levels of the di-and triphosphate were low (c5 MuM and <2 MuM, respectively).
azidothymidine was equal to 60% of the rate with thymidine. Phosphorylation of azidothymidine monophosphate to the diphosphate also appeared to be catalyzed by a host-cell enzyme, thymidylate kinase (EC 2.7.4.9). The apparent Km value for azidothymidine monophosphate was 2-fold greater than the value for dTMP (8.6 ,uM vs. 4.1 MM), but the maximal phosphorylation rate was only 0.3% of the dTMP rate. These kinetic constants were consistent with the anabolism results and indicated that azidothymidine monophosphate is an alternative-substrate inhibitor of thymidylate kinase. This conclusion was reflected in the observation that cells incubated with azidothymidine had reduced intracellular levels of dTTP. ICso (concentration of inhibitor that inhibits enzyme activity 50%) values were determined for azidothymidine triphosphate with HYIV reverse transcriptase and with immortalized human lymphocyte (H9 cell) DNA polymerase a. Azidothymidine triphosphate competed about 100-fold better for the HIV reverse transcriptase than for the cellular DNA polymerase a. The results reported here suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate derivative efficiently and selectively binds to the HIV reverse transcriptase. Incorporation of azidothymidylate into a growing DNA strand should terminate DNA elongation and thus inhibit DNA synthesis.
Recently, Mitsuya et al. (1) reported that 3'-azido-3'-deoxythymidine (azidothymidine) was a selective and potent inhibitor of human T-cell lymphotropic virus type III (HTLV-III, now called human immunodeficiency virus, HIV) replication in several different lymphocyte cultures. Many other thymidine analogs are known to inhibit other viruses in cell culture with varying degrees of selectivity (2, 3) . Selectivity of activation can result from increased levels of cytosolic or virus-encoded thymidine kinase in the infected cells. Although the monophosphate of some analogs can inhibit thymidylate synthase, a more common target for interaction is the virus-encoded DNA polymerase. Selectivity at this level results from a higher affinity of the analog triphosphate for the viral polymerase than for cellular polymerase(s). Incorporation of the analog monophosphate into viral DNA may be a critical event for some analogs (2) .
Whether any of these modes of selectivity or targets of inhibition pertain to the selective inhibition of HIV by azidothymidine was not known. The retroviruses are not known to code for a thymidine kinase, and the viral polymerase for which they code (RNA-directed DNA polymerase, reverse transcriptase, EC 2.7.7.49) is catalytically quite distinct from cellular DNA polymerases (4, 5) . An additional aspect to the mode of action of azidothymidine is that the 3'-azido group should cause termination of DNA elongation if the nucleoside moiety were incorporated into DNA.
Here we show that azidothymidine is phosphorylated to its 5'-triphosphate derivative by cellular enzymes of the thymidine-phosphorylation pathway [ (12) and was purified with a Mono Q column (Pharmacia) at pH 2.8. Other chemicals were as used previously (12) .
Cell Growth and Cytotoxicity Assays. The effect of azidothymidine on cell growth was measured in a 72-hr growth-inhibition assay described previously (13) . Cell cytotoxicity using clone H9 cells and phytohemagglutininstimulated PBLs was determined by erythrosin B exclusion after incubation with various concentrations of azidothymidine for 72 hr at 37°C. H9 cells and PBLs were cultured in medium containing various concentrations of drug at 2 x 105 and 5 x 10-cells per ml, respectively.
Enzyme Preparations. Cell extracts were 10,000 x g supernatants of frozen-thawed (three cycles) H9 cell pellets in four volumes of extraction buffer (10 mM Tris-HCl, pH 7.5/10 mM KCl/1 mM MgCl2/1 mM dithiothreitol). Cytosolic thymidine kinase and thymidylate kinase from H9 cells were purified by affinity chromatography as described (12) . Enzyme was stored in elution buffer and desalted by sizeexclusion chromatography just before use. Less than 1% dTMP-or dTDP-phosphohydrolyzing activity was detected with either enzyme.
HIV reverse transcriptase was purified by a modification of the procedure of Abrell and Gallo (14) . In brief, 750 ml of culture fluid harvested from HIV-infected H9 cells was centrifuged at 18,000 rpm for 90 min in an R19 rotor (Beckman) to pellet virus. Enzyme was extracted by incubating the virus pellet in buffer A [50 mM Tris-HCl, pH 7.9/0.25% Nonidet P-40/20 mM dithiothreitol/5% (vol/vol) glycerol] containing 1 mM EDTA, 500 mM KCl, and 0.5% deoxycholate. The enzyme was partially purified by passing the extract through a DEAE-cellulose column (3 x 10 cm) previously equilibrated with buffer A. Fractions containing enzyme activity were dialyzed against buffer B (50 mM Tris HCl, pH 7.9/50 mM NaCl/1 mM EDTA/1 mM dithiothreitol/20% glycerol) and were further purified by phosphocellulose chromatography. The peak fractions were pooled and dialyzed against buffer B containing 50% glycerol. To the dialyzed enzyme, bovine serum albumin was added to give a final concentration of 1 mg/ml. The enzyme was characterized as HIV reverse transcriptase based on its cation, salt, pH, and template requirements (5) . Cellular DNA polymerase a was purified as described (15) .
Enzyme Assays. Phosphorylation of thymidine, azidothymidine, or their monophosphates was measured at 370C by a DEAE-paper disk method (16) or by measuring the conversion of the substrate to product by excision and scintillation counting of the appropriate portions of polyethylenimine thin-layer plates (12, 16) (12) . One unit of enzyme activity was defined as the amount of enzyme that would convert 1 pmol of thymidine or dTMP to its phosphorylated product per minute under the above standard conditions.
The purified HIV reverse transcriptase was assayed using reaction conditions similar to those of Abrell and Gallo (14) and adapted to the DEAE-paper disk assay (15) . Reaction mixtures (150 ,ul) contained 50 mM Tris HCl (pH 7.3); 100 mM KCl; 5 mM MgCl2; 1 mM dithiothreitol; 80 ,M each dATP, dCTP, and dGTP; and 5.6 ,M [3H]dTTP (4800 cpm/pmol), unless otherwise stated. The template concentration was 20 ,ug/ml for poly(rA)-oligo(dT)j2_j8 (Pharmacia P-L Biochemicals) and for activated calf thymus DNA. Cellular DNA polymerase a was assayed as described (15) .
ICs0 values (concentration of inhibitor that inhibits enzyme activity by 50%) for HIV reverse transcriptase and H9 DNA polymerase a were calculated using the Probit computer program (17) .
High-Performance Liquid Chromatography Analysis. Neutralized perchloric acid extracts of cells treated with 50 ,M [3H]azidothymidine were analyzed by HPLC as described (18) . Azidothymidine nucleotides were separated by elution with a linear gradient of 0.015-1 M KH2PO4 (pH 3.5), developed over 110 min at a flow rate of 0.5 ml/min. Intracellular levels of deoxyribonucleoside triphosphates were quantitated as described (19) .
Identification of Phosphorylated Products. Phosphorylated products obtained from cells or from phosphorylation of azidothymidine catalyzed by cell extracts were identified as 5'-phosphates of azidothymidine by treatment of the products with Crotalus atrox phosphodiesterase I (EC 3.1.4.1), which hydrolyzed the di-and triphosphates completely to the monophosphate, and then with C. atrox 5'-nucleotidase (EC 3.1.3.5) to produce the nucleoside analog. Subsequent cochromatography with azidothymidine through a C18 reversed-phase column (retention volume 5.8 ml in 30% methanol) confirmed that the analog was, in fact, azidothymidine.
RESULTS
Effects of Azidothymidine on Cell Growth and Viability. The effect of azidothymidine on cell growth varied with cell type (Table 1) . Human fibroblasts and lymphocytes showed little inhibition of growth except at very high concentrations (ID50 -1000 ,M), whereas epithelial cells of murine and primate origin were somewhat more sensitive (ID50 = 30 and 170 ,uM, respectively). This variation in sensitivity to azidothymidine appeared to correlate with levels of azidothymidine 5'-triphosphate in these cells (unpublished observations). Cytotoxicity assays with H9 cells and PBLs also required high concentrations of azidothymidine (-500 ,M) to achieve the 50% end point ( Table 1) .
Anabolism of Azidothymidine. The nucleotide profile revealed the presence of radioactivity in the mono-, di-, and triphosphate regions of the chromatogram (Fig. 1) . Occasionally, minor peaks at about 19 min (<1% of total) and 47 min (<0.3% of total) were observed. The material at about 17 min was azidothymidine and was calculated to be less than or equal to the concentration of azidothymidine in the medium. The major derivatives were identified as 5'-phosphates of azidothymidine (see Materials and Methods). High concentrations of azidothymidine monophosphate were detected in the uninfected and the HIV-infected H9 cells ( Fig. 1 and Table 2 ), whereas the levels of the diphosphate and triphosphate were low. By 24 hr these phosphorylated derivatives had accumulated maximally. Even though the level of azidothymidine monophosphate that accumulated during a 24-hr exposure to azidothymidine decreased somewhat throughout the replication cycle of the virus, no significant differences were noted in the levels of the di-and triphosphate derivatives. Increasing the time that the cells were exposed to the drug did not result in higher levels of phosphorylated derivatives.
The decrease in levels of the phosphorylated derivatives of azidothymidine, after removal of the drug from the incubation medium, was measured during peak virus replication (days 5-6). HIV-infected cells were incubated for 24 hr in medium containing 50 ,uM [3H]azidothymidine, after which the cells were washed and the incubation was continued in drug-free medium. Perchloric acid extracts for HPLC analysis were then prepared at various times during the incubation. Under these conditions, the levels of the phosphorylated derivatives of azidothymidine declined rapidly with time (Table 3) . However, 4 hr after removal of azidothymidine, the intracellular concentration of the triphosphate was still 1 ,uM. Phosphorylation of Azidothymidine with Cell Extracts and Purified Enzymes. The structural similarity ofazidothymidine to thymidine suggested that thymidine kinase might catalyze the phosphorylation of the analog. With cell extracts, thymidine and azidothymidine (100 jIM) were phosphorylated at rates of 26 and 17 pmol/min per 106 viable cells, respectively. There was no apparent virus stimulation of these activities during a 10-day course of HIV infection.
Phosphorylation of azidothymidine catalyzed by cell extracts was totally inhibited by thymidine; conversely, thymidine phosphorylation was inhibited by azidothymidine. This suggested that azidothymidine and thymidine phosphorylations were catalyzed by a single enzyme. Calculations from inhibition data, assuming an apparent Km value for thymidine of 3 AM (20) , indicated a K1 value for azidothymidine of about 2 ,uM. The values of relative phosphorylation rates and apparent Km values from extracts were compared to values obtained with purified cytosolic thymidine kinase from H9 cells. Azidothymidine was phosphorylated with a maximal velocity 60% that ofthymidine and with an apparent Km value of 3.0 ,M compared to a value of 2.9 ,uM for thymidine (Table 4 ). These phosphorylation rates and Km values determined with the purified enzyme corresponded well with the values obtained with the cell extracts (see above). This correspondence supported the premise that azidothymidine phosphorylation is catalyzed by the thymidine kinase of the cell.
Phosphorylation of azidothymidine monophosphate to the diphosphate appeared to be catalyzed by thymidylate kinase. Phosphorylation of azidothymidylate catalyzed by extracts 8.6 ,uM (Fig. 2) . The apparent Km value for dTMP (4.1 ,uM) was identical to that determined by Chen et al. (21) with enzyme from Vero cells.
Radiolabeled azidothymidylate was used to compare the rate of phosphorylation to that of dTMP. Its relative maximal velocity was very low (Table 4 ). In spite of the low rate, since azidothymidylate was a substrate for the dTMP kinase, its apparent Km value is equal to the Kis value determined above (22) . Because of the low Km and low Vmax values for azidothymidylate, it can be considered an effective alternative-substrate inhibitor of dTMP kinase.
Effect of Azidothymidine on Intracellular Deoxyribonucleoside Triphosphate Levels. In three separate experiments, intracellular dTTP levels were severely reduced when H9 cells were exposed to 50 ,uM azidothymidine (Table 5 ). In addition to the effect on dTTP levels, a large decrease in dCTP levels, an -50% decrease in dGTP levels, and a significant increase in dATP levels were observed. A similar trend was observed with HIV-infected H9 cells after exposure to 50 ,M azidothymidine for 24 and 48 hr during the period of peak virus replication (days 5-7).
Azidothymidine Triphosphate Inhibits [3H]dTMP Incorporation Catalyzed by HIV Reverse Transcriptase. The ability of azidothymidine triphosphate to bind to the HIV reverse transcriptase and DNA polymerase a of H9 cells was assessed by measuring the inhibition of [3H]dTMP incorporation into a primer-template by azidothymidine triphosphate. The reverse transcriptase was much more sensitive to inhibition than was the DNA polymerase a of H9 cells (Fig.  3) 
DISCUSSION
The thymidine analog 3'-azido-3'-deoxythymidine is a potent inhibitor of HIV replication in vitro (1) and shows little effect on the growth of cultured human fibroblasts and lymphocytes (Table 1 ). The in vitro "therapeutic index" (concentration that inhibits cell growth 50% divided by the concentration that inhibits virus replication 50%) for azidothymidine with the target H9 cells or PBLs was 2104. These results suggest that, in these cells, azidothymidine is a highly selective inhibitor of HIV replication.
Anabolism and enzyme experiments showed that a virusencoded or virus-induced enzyme played no role in the anabolic activation of azidothymidine. This analog was a good substrate for the cellular thymidine kinase and was phosphorylated as efficiently as thymidine. This observation contrasts with the activation of acyclovir by a virus-encoded rather than cellular thymidine kinase (16) .
The second phosphorylation step for azidothymidine was catalyzed by the cellular dTMP kinase. Contrary to the case with thymidine kinase, the dTMP kinase phosphorylated azidothymidylate only inefficiently. This was consistent with the idea that dTMP kinase catalyzed the rate-limiting step in the anabolism of azidothymidine to the triphosphate.
Because the levels of azidothymidylate in azidothymidinetreated H9 cells were so high, we cannot rule out the Azidothymidine triphosphate inhibited HIV reverse transcriptase -100 times better than it inhibited the H9 polymerase a, with activated calf thymus DNA as the template. When transcription of the viral RNA template was mimicked by using poly(rA) oligo(dT)12_j8, the reverse transcriptase was 300 times more sensitive to inhibition.
Because the levels of azidothymidine triphosphate were low in HIV-infected cells incubated with azidothymidine, the question can be raised whether there is enough triphosphate present to bind to and possibly be a substrate for the reverse transcriptase. In these studies, intracellular levels of 1-7 ,uM azidothymidine triphosphate were observed. Preliminary kinetic data with the HIV reverse transcriptase suggest that these levels of triphosphate in the infected cells are 25-to 160-fold greater than the Ki, (0.04 ,M). Further, when azidothymidine was removed from infected cultures, the analog triphosphate persisted at concentrations 25 times the Ki for the reverse transcriptase for at least 4 hr during peak virus replication.
Exposure of cells to azidothymidine caused a reduction in the intracellular level of dTTP. This effect may play a role in the inhibition of HIV DNA synthesis, because reducing the level of the competing substrate, dTTP, would facilitate the binding of azidothymidine triphosphate to the reverse transcriptase. In addition to a role in the antiviral effect of azidothymidine, the changes in the intracellular levels of the deoxynucleoside triphosphates may play some role in the cytotoxicity observed in the 72-hr growth studies.
The data indicate that azidothymidine is anabolized as a thymidine analog in the first two phosphorylation steps and that these are catalyzed by cellular enzymes. Azidothymidine triphosphate preferentially interacts with the HIV reverse transcriptase. Preliminary evidence also suggests that azidothymidine triphosphate can serve as an alternative substrate for the reverse transcriptase and that incorporation of azidothymidylate into a DNA primer-template results in chain termination (23) . This highly selective incorporation into and chain termination of viral DNA synthesis via the reverse transcriptase appears to explain the high selectivity of azidothymidine for HIV compared with normal host cells.
